Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2009

Open Access 01-12-2009 | Research article

The Ets dominant repressor En/Erm enhances intestinal epithelial tumorigenesis in ApcMin mice

Authors: Paul Jedlicka, Xiaomei Sui, Arthur Gutierrez-Hartmann

Published in: BMC Cancer | Issue 1/2009

Login to get access

Abstract

Background

Ets transcription factors have been widely implicated in the control of tumorigenesis, with most studies suggesting tumor-promoting roles. However, few studies have examined Ets tumorigenesis-modifying functions in vivo using model genetic systems.

Methods

Using mice expressing a previously characterized Ets dominant repressor transgene in the intestinal epithelium (Villin-En/Erm), we examined the consequences of blocking endogenous Ets-mediated transcriptional activation on tumorigenesis in the ApcMin model of intestinal carcinoma.

Results

En/Erm expression in the intestine, at levels not associated with overt crypt-villus dysmorphogenesis, results in a marked increase in tumor number in ApcMin animals. Moreover, when examined histologically, tumors from En/Erm-expressing animals show a trend toward greater stromal invasiveness. Detailed analysis of crypt-villus homeostasis in these En/Erm transgenic animals suggests increased epithelial turnover as one possible mechanism for the enhanced tumorigenesis.

Conclusion

Our findings provide in vivo evidence for a tumor-restricting function of endogenous Ets factors in the intestinal epithelium.
Appendix
Available only for authorised users
Literature
1.
Oikawa T, Yamada T: Molecular biology of the Ets family of transcription factors. Gene. 2003, 303: 11-34. 10.1016/S0378-1119(02)01156-3.CrossRefPubMed
2.
Sharrocks AD: The ETS-domain transcription factor family. Nat Rev Mol Cell Biol. 2001, 2 (11): 827-837. 10.1038/35099076.CrossRefPubMed
3.
Feldman RJ, Sementchenko VI, Watson DK: The epithelial-specific Ets factors occupy a unique position in defining epithelial proliferation, differentiation and carcinogenesis. Anticancer Res. 2003, 23 (3A): 2125-2131.PubMed
4.
5.
Seth A, Watson DK: ETS transcription factors and their emerging roles in human cancer. Eur J Cancer. 2005, 41 (16): 2462-2478. 10.1016/j.ejca.2005.09.005.CrossRefPubMed
6.
Man AK, Young LJ, Tynan JA, Lesperance J, Egeblad M, Werb Z, Hauser CA, Muller WJ, Cardiff RD, Oshima RG: Ets2-dependent stromal regulation of mouse mammary tumors. Mol Cell Biol. 2003, 23 (23): 8614-8625. 10.1128/MCB.23.23.8614-8625.2003.CrossRefPubMedPubMedCentral
7.
Shepherd TG, Kockeritz L, Szrajber MR, Muller WJ, Hassell JA: The pea3 subfamily ets genes are required for HER2/Neu-mediated mammary oncogenesis. Curr Biol. 2001, 11 (22): 1739-1748. 10.1016/S0960-9822(01)00536-X.CrossRefPubMed
8.
Tynan JA, Wen F, Muller WJ, Oshima RG: Ets2-dependent microenvironmental support of mouse mammary tumors. Oncogene. 2005, 24 (46): 6870-6876. 10.1038/sj.onc.1208856.CrossRefPubMed
9.
Jedlicka P, Gutierrez-Hartmann A: Ets transcription factors in intestinal morphogenesis, homeostasis and disease. Histol Histopathol. 2008, 23 (11): 1417-1424.PubMedPubMedCentral
10.
Jedlicka P, Sui X, Sussel L, Gutierrez-Hartmann A: Ets transcription factors control epithelial maturation and transit and crypt-villus morphogenesis in the mammalian intestine. Am J Pathol. 2009, 174 (4): 1280-1290. 10.2353/ajpath.2009.080409.CrossRefPubMedPubMedCentral
11.
Hollenhorst PC, Jones DA, Graves BJ: Expression profiles frame the promoter specificity dilemma of the ETS family of transcription factors. Nucleic Acids Res. 2004, 32 (18): 5693-5702. 10.1093/nar/gkh906.CrossRefPubMedPubMedCentral
12.
Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C, Gould KA, Dove WF: Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science. 1992, 256 (5057): 668-670. 10.1126/science.1350108.CrossRefPubMed
13.
Heyer J, Yang K, Lipkin M, Edelmann W, Kucherlapati R: Mouse models for colorectal cancer. Oncogene. 1999, 18 (38): 5325-5333. 10.1038/sj.onc.1203036.CrossRefPubMed
14.
Boivin GP, Washington K, Yang K, Ward JM, Pretlow TP, Russell R, Besselsen DG, Godfrey VL, Doetschman T, Dove WF, et al: Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology. 2003, 124 (3): 762-777. 10.1053/gast.2003.50094.CrossRefPubMed
15.
Lawrance AK, Deng L, Brody LC, Finnell RH, Shane B, Rozen R: Genetic and nutritional deficiencies in folate metabolism influence tumorigenicity in Apcmin/+ mice. J Nutr Biochem. 2007, 18 (5): 305-312. 10.1016/j.jnutbio.2006.06.001.CrossRefPubMed
16.
Dietrich WF, Lander ES, Smith JS, Moser AR, Gould KA, Luongo C, Borenstein N, Dove W: Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse. Cell. 1993, 75 (4): 631-639. 10.1016/0092-8674(93)90484-8.CrossRefPubMed
17.
Gould KA, Luongo C, Moser AR, McNeley MK, Borenstein N, Shedlovsky A, Dove WF, Hong K, Dietrich WF, Lander ES: Genetic evaluation of candidate genes for the Mom1 modifier of intestinal neoplasia in mice. Genetics. 1996, 144 (4): 1777-1785.PubMedPubMedCentral
18.
Madison BB, Dunbar L, Qiao XT, Braunstein K, Braunstein E, Gumucio DL: Cis elements of the villin gene control expression in restricted domains of the vertical (crypt) and horizontal (duodenum, cecum) axes of the intestine. J Biol Chem. 2002, 277 (36): 33275-33283. 10.1074/jbc.M204935200.CrossRefPubMed
19.
Sussan TE, Yang A, Li F, Ostrowski MC, Reeves RH: Trisomy represses Apc(Min)-mediated tumours in mouse models of Down's syndrome. Nature. 2008, 451 (7174): 73-75. 10.1038/nature06446.CrossRefPubMed
Metadata
Title
The Ets dominant repressor En/Erm enhances intestinal epithelial tumorigenesis in ApcMin mice
Authors
Paul Jedlicka
Xiaomei Sui
Arthur Gutierrez-Hartmann
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2009
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-9-197

Other articles of this Issue 1/2009

BMC Cancer 1/2009 Go to the issue

Study protocol

Cancer Health Empowerment for Living without Pain (Ca-HELP): study design and rationale for a tailored education and coaching intervention to enhance care of cancer-related pain

Research article

The intraportal injection model: A practical animal model for hepatic metastases and tumor cell dissemination in human colon cancer

Research article

Clinical significance of Neutrophil gelatinase-associated lipocalin(NGAL) expression in primary rectal cancer

Research article

Pediatric differentiated thyroid carcinoma in stage I: risk factor analysis for disease free survival

Research article

APRIL is overexpressed in cancer: link with tumor progression

Research article

Neoadjuvant chemotherapy or primary surgery for stage III/IV ovarian cancer: contribution of diagnostic laparoscopy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits